Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Blood

• Publication date

  1993-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V81.11.2878.BLOODJOURNAL81112878PMID 8499626
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.

  1992cited by this paper
• Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis.

  1992cited by this paper
• A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.

  1991cited by this paper
• 2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia.

  1991cited by this paper
• Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

  1991cited by this paper
• Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial.

  1991cited by this paper
• 2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside.

  1991cited by this paper
• Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients.

  1991cited by this paper
• Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.

  1989cited by this paper
• Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.

  1988cited by this paper
• A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C.

  1988cited by this paper
• Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia.

  1988cited by this paper
• Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group

  1988cited by this paper
• 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia.

  1988cited by this paper
• Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity.

  1987cited by this paper
• Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle‐active consolidation chemotherapy .A southeastern cancer study group trial

  1986cited by this paper
• Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone

  1985cited by this paper
• Low-dose deoxycoformycin in lymphoid malignancy.

  1985cited by this paper
• Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite.

  1984cited by this paper
• Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone).

  1982cited by this paper
• Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. Richter's syndrome: A study of 25 cases

  1981cited by this paper
• [Richter's syndrome].

  1980cited by this paper
• Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in the treatment of refractory chronic lymphocytic leukemia.

  1979cited by this paper

• Chronische lymphatische Leukämie

  2020cites this paper
• BCL2 Inhibitors: Insights into Resistance

  2018cites this paper
• Epidemiology of most frequent infectious complications in immunocompromised patients: focusing on bacteraemia, CMV and HHV-6 infections in haematological patients, and following autologous stem cell transplantation

  2017cites this paper
• High ten‐year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R‐FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

  2017cites this paper
• Idelalisib- a PI3Kδ targeting agent for B-cell malignancies

  2016cites this paper
• Initial therapy of chronic lymphocytic leukemia.

  2016cites this paper
• prospective, randomized, multicenter trial first-line therapy in chronic lymphocytic leukemia: report of a Cladribine with prednisone versus chlorambucil with prednisone as

  2013cites this paper
• Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia

  2013cites this paper
• Proteomic analysis of HSP90 inhibitor effects on human leukemia cells

  2013cites this paper
• Fludarabine: a review of the clear benefits and potential harms.

  2013cites this paper
• and Fludarabine in Patients With Chronic Lymphocytic Leukemia Phase-II Study of a combined Immuno-Chemotherapy using Rituximab

  2013cites this paper
• Leucemia linfocítica crónica: sospecha y confirmación del diagnóstico; tratamiento

  2012cites this paper
• Evaluation of LMP-420: A Novel, Nontoxic Drug with Anti-Inflammatory Properties and Therapeutic Potential for CLL

  2012cites this paper
• Achieving Optimal Outcomes in Chronic Lymphocytic Leukaemia

  2012cites this paper
• Clinical Experience with Fludarabine in Leukaemia

  2012cites this paper
• Infectious Complications in Chronic Lymphocytic Leukemia

  2012cites this paper
• Immunological and Genetic Abnormalities in Chronic Lymphocytic Leukaemia

  2012cites this paper
• Evolution of the Arabinosides and the Pharmacology of Fludarabine

  2012cites this paper
• Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.

  2012cites this paper
• Young patients with chronic lymphocytic leukaemia.

  2011cites this paper
• Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease

  2011cites this paper
• Leucémie lymphoïde chronique : quand l'évoquer, comment l'affirmer ? Quels en sont les traitements ?

  2011cites this paper
• Evaluation of Treatment Results of Patients Treated with Splenectomy due to Hematological Cancer

  2011cites this paper
• Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011.

  2011cites this paper
• leukemia Advances in the biology and treatment of B-cell chronic lymphocytic

  2011cites this paper
• Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches.

  2010cites this paper
• The spectrum of use of rituximab in chronic lymphocytic leukemia

  2010cites this paper
• Monoclonal Antibody Therapy for Hematologic Malignancies

  2010cites this paper
• The spectrum of use of rituximab in chronic lymphocytic leukemia

  2010cites this paper
• Chronic lymphocytic leukemia.

  2010cites this paper
• Chronic Lymphocytic Leukemia Associated with Myelodysplastic Syndrome with Ring Sideroblasts

  2010cites this paper
• Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.

  2009cites this paper
• Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma

  2009cites this paper
• Frontline therapy for chronic lymphocytic leukemia patients.

  2009cites this paper
• Valproate synergizes with purine nucleoside analogues to induce apoptosis of B‐chronic lymphocytic leukaemia cells

  2009cites this paper
• Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases

  2009cites this paper
• Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia

  2009cites this paper
• Fludarabine in the treatment of chronic lymphocytic leukemia: a review

  2009cites this paper
• Alemtuzumab in the treatment of fl udarabine refractory B-cell chronic lymphocytic leukemia (CLL)

  2008cites this paper
• Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

  2008cites this paper
• Targeted Therapy in Chronic Lymphocytic Leukemia

  2008cites this paper
• Frontline Therapy of Chronic Lymphocytic Leukemia

  2008cites this paper
• Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)

  2008cites this paper
• Hypertension Congestive heart failure Peripheral vascular disease Cerebrovascular disease Angina Cardiac arrhythmia Myocardial infarction

  2008cites this paper
• Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration

  2008cites this paper
• High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia

  2008cites this paper
• Infectious Complications in Patients with Chronic Lymphocytic Leukemia

  2008cites this paper
• The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas

  2007cites this paper
• Recent progress in the management of chronic lymphocytic leukemia.

  2007cites this paper
• Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.

  2007cites this paper
• Management of infectious complications in patients with chronic lymphocytic leukemia.

  2007cites this paper
• Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

  2007cites this paper
• Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents.

  2007cites this paper
• Emerging therapy for chronic lymphocytic leukaemia

  2007cites this paper
• hronic Lymphocytic Leukemia

  2007cites this paper
• Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia

  2006cites this paper
• Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.

  2006cites this paper
• Leucémie lymphoïde chronique

  2006cites this paper
• Chronic Lymphocytic Leukemia and Related Chronic Leukemias

  2006cites this paper
• Fludarabine in chronic lymphocytic leukaemia

  2006influential citation
• Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.

  2006cites this paper
• Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.

  2006cites this paper
• High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission

  2006cites this paper
• Chronic lymphocytic leukemia: diagnosis and treatment.

  2006cites this paper
• The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.

  2005cites this paper
• Monoclonal antibody therapy of leukaemias and lymphomas

  2005cites this paper
• High Molecular Weight DNA Fragmentation: A Critical Event in Nucleoside Analogue-induced Apoptosis in Leukemia Cells1

  2005cites this paper
• Chronic Lymphocytic Leukemia and Associated Disorders

  2005cites this paper
• HEMATOLOGICAL RECOVERY AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR HIGH-GRADE NON HODGKIN ’ S LYMPHOMAS : A SINGLE CENTER EXPERIENCE

  2005cites this paper
• Changing the way we think about chronic lymphocytic leukemia.

  2005cites this paper
• The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland

  2005cites this paper
• Infections associated with purine analogs and monoclonal antibodies.

  2005cites this paper
• Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal.

  2005cites this paper
• Mechanisms of Cell Death of Chronic Lymphocytic Leukemia Lymphocytes by RNA-Directed Agent, 8-NH2-Adenosine

  2005cites this paper
• Therapy of Chronic Lymphocytic Leukaemia with Purine Nucleoside Analogues

  2005cites this paper
• Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen

  2005cites this paper
• Salvage therapy for CLL and the role of stem cell transplantation.

  2005cites this paper
• Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia

  2005cites this paper
• Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).

  2005cites this paper
• Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H

  2004cites this paper
• Platelet Kinetics and Decreased Transfusion Requirements After Splenectomy for Hematologic Malignancy

  2004cites this paper
• Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine.

  2004cites this paper
• Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology

  2004cites this paper
• A new model for predicting infectious complications during fludarabine‐based combination chemotherapy among patients with indolent lymphoid malignancies

  2004cites this paper
• The role of stem cell transplantation in chronic lymphocytic leukemia.

  2004cites this paper
• An update on the management of chronic lymphocytic leukaemia

  2004cites this paper
• Chronic lymphocytic leukemia.

  2004cites this paper
• Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia.

  2004cites this paper
• Flavopiridol: where do we stand in chronic lymphocytic leukemia?

  2004cites this paper
• Treatment of Resistant/Relapsing Chronic Lymphocytic Leukemia with a Combination Regimen Containing Deoxycoformycin and Rituximab

  2004cites this paper
• Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.

  2004cites this paper
• Second Malignancies and Richter's Syndrome in Patients with Chronic Lymphocytic Leukemia

  2004cites this paper
• Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia.

  2004cites this paper
• Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.

  2004cites this paper
• Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia

  2004cites this paper
• Advances in chemotherapy for chronic lymphocytic leukemia.

  2004cites this paper
• Monoclonal antibody therapy in lymphoid leukemias.

  2004cites this paper
• High incidence of complications after 2-chloro-2’-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies

  2004cites this paper
• Drug-induced pulmonary infection.

  2004cites this paper
• Role of IMP-SELECTIVE 5′-NUCLEOTIDASE (cN-II) in HEMATOLOGICAL MALIGNANCIES

  2003cites this paper